BioSpace News Archive

Drug Development

Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

Auris Medical Holding Ltd. announced that it has reached the midpoint for enrollment in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.

May 7, 2019
·
5 min read
Deals

ADL Bionatur Solutions Reports Strong Financial Results For The First Quarter Of 2019

ADL Bionatur Solutions advances the results of selected key performance indicators for the first quarter of 2019 ending March 31, 2019.

May 7, 2019
·
4 min read
Deals

MorphoSys AG Reports First Quarter 2019 Results

MorphoSys AG reports results for the first quarter of 2019.

May 7, 2019
·
15 min read
Drug Development

Merck Ready to Submit Belsomra to FDA for Alzheimer’s Insomnia

The company announced today that it had positive results in a Phase III clinical trial evaluating the drug for insomnia in patients with mild-to-moderate Alzheimer’s disease dementia.

May 7, 2019
·
2 min read
·
Mark Terry
Business

Verve Therapeutics Explodes out of Stealth Mode to Focus on Gene Therapies for Cardiovascular Disease

Verve Therapeutics launched with a $58.5 million Series A financing round. It was led by GV (formerly Google Ventures).

May 7, 2019
·
3 min read
·
Mark Terry
FDA

FDA Had Questions About Novartis’ Data Practices During Mayzent MS Approval

On March 27, the U.S. Food and Drug Administration (FDA) approved Novartis’ Mayzent (isiponimod) for adults with relapsing types of multiple sclerosis.

May 7, 2019
·
3 min read
·
Mark Terry
Business

Interview: As Gene and Cell Therapies Grow, Reimbursement Model Needs to Change

Although the advent of cell and gene therapies is revolutionizing medicine, it is arguable that the therapies that have been approved to date in this area aren’t living up to expectations.

May 7, 2019
·
6 min read
·
Mark Terry
Reuters to make documentary on Paras Biopharmaceuticals Finland Oy - Innovations in Biologics: Insights of a leading expert

Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected our Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions.

May 7, 2019
·
2 min read
Policy

Evotec SE To Report First Quarter 2019 Results On 14 May 2019

Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.

May 7, 2019
·
3 min read
FDA

Catalyst Shares Plunge Following FDA Approval of Rival LEMS Drug

The Jacobus LEMS Drug was approved for pediatric patients. However, the approval was based on results from a study of adult patients, which means that doctors could opt to prescribe this medication for adult LEMS patients.

May 7, 2019
·
2 min read
·
Alex Keown